Skip to main content

Advertisement

SpringerLink
Log in

Bones, Fractures, Antiretroviral Therapy and HIV

  • HIV/AIDS (R MacArthur, Section Editor)
  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

The course of HIV infection has been dramatically transformed by the success of antiretroviral therapy from a universally fatal infection to a manageable chronic disease. With these advances in HIV disease management, age-related comorbidities, including metabolic bone disease, have become more prominent in the routine care of persons living with HIV infection. Recent data have highlighted the role of HIV infection, initiation of antiretroviral therapy, and hepatitis C virus coinfection in bone mineral density loss and fracture incidence. Additionally, the underlying mechanism for the development of metabolic bone disease in the setting of HIV infection has received considerable attention. This review highlights recently published and presented data and synthesizes the current state of the field. These data highlight the need for proactive prevention for fragility fractures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Effros RB, Fletcher CV, Gebo K, et al. Aging and infectious diseases: w1. Effros RB, Fletcher CV, Gebo K, et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis. 2008;47(4):542–53.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Onen NF, Overton ET, Seyfried W, et al. Aging and HIV infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials. 2010;11(2):100–9.

    Article  PubMed  Google Scholar 

  3. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20(17):2165–74.

    Article  PubMed  Google Scholar 

  4. Overton ET, Mondy K, Bush TJ, et al. Factors associated with low bone mineral density (BMD) in a cohort of HIV-infected U.S. adults – Baseline results from the SUN Study. Los Angeles: Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections; 2002. Abstract 836.

    Google Scholar 

  5. Guaraldi G, Orlando G, Squillace N, et al. Prevalence of secondary causes of osteoporosis among HIV-infected individuals. Antiviral Ther. 2006;11(7):L9.

    Google Scholar 

  6. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008;93(9):3499–504.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Negredo E, Domingo P, Perez-Alvarez N, et al. Multicenter randomized study to assess changes in HIV subjects with low bone mineral density after switching from tenofovir to abacavir: OsteoTDF Study. Atlanta: Proceedings of the 20th Conference on Retroviruses and Opportunistic Infections; 2013. Abstract 824.

    Google Scholar 

  8. Bloch M, Tong W, Hoy J, et al. Improved low BMD and bone turnover markers with switch from tenofovir to raltegravir in virologically suppressed HIV-1+ adults at 48 weeks: the TROP Study. Seattle: Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections; 2012. Abstract 878.

    Google Scholar 

  9. Bedimo R, Drechsler H, Cutrell J, et al. RADAR study: week 48 safety and efficacy of raltegravir combined with boosted DRV compared to tenofovir/emtricitabine combined with boosted DRV in antiretroviral-naive patients. Impact on bone health. Kuala Lumpur: Proceedings of the 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2012. Abstract WEPE512.

    Google Scholar 

  10. Martin A, Moore C, Mallon PW, et al. Changes in bone mineral density over 48 weeks among participants randomised to either lopinavir/ritonavir (LPV/r) + 2-3N(t)RTI or LPV/r + raltegravir as second-line therapy: a sub-study of the SECONDLINE trial. Kuala Lumpur: Proceedings of the 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2013. Abstract WELBB05.

    Google Scholar 

  11. Overton ET, Greenberg K, Benson P, et al. Immune activation analysis over 48 weeks in INROADS, a study of the nucleoside/tide-sparing regimen of once-daily etravirine and darunavir/ritonavir. Brussels: Proceedings of the 15th International Workshop on Comorbidities and Adverse Drug Reactions in HIV; 2013. Abstract P03.

    Google Scholar 

  12. Moyle GJ, Stellbrink HJ, Compston J, et al. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. Antivir Ther. 2013. doi:10.3851/IMP2667.

    PubMed  Google Scholar 

  13. Wohl D, Bhatti L, Small CB, et al. Simplification to abacavir/lamivudine (ABC/3TC) + atazanavir (ATV) from tenofovir/emtricitabine (TDF/FTC) + ATV/ritonavir (r) maintains viral suppression and improves bone biomarkers: 48 week ASSURE study results. Denver: Proceedings of the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2013. Abstract H-665.

    Google Scholar 

  14. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203(12):1791–801. This randomized study confirms that ART initiation, regardless of selection of specific agents, induces significant bone loss. Additionally, tenofovir-based regimens, regardless of choice of protease inhibitor or NNRTI, result in greater losses in BMD.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Brown TT, Ross AC, Storer N, et al. Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. Antivir Ther. 2011;16(7):1063–72.

    Article  CAS  PubMed  Google Scholar 

  16. Zolopa A, Ortiz R, Sax P, et al. Comparative study of tenofovir alafenamide vs tenofovir disoproxil fumarate, each with elvitegravir, cobicistat, and emtricitabine, for HIV treatment. Atlanta: Proceedings of the 20th Conference on Retroviruses and Opportunistic Infections; 2013. Abstract 99LB.

    Google Scholar 

  17. Sax P, Brar I, Elion R, et al. 48 Week study of tenofovir alafenamide (TAF) vs. tenofovir disoproxil fumarate (TDF), each in a single tablet regimen (STR) with elvitegravir, cobicistat, and emtricitabine [E/C/F/TAF vs. E/C/F/TDF] for Initial HIV treatment. Denver: Proceedings of the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2013. Abstract H-1464d.

    Google Scholar 

  18. Tanchaweng S, Puthanakit T, Saksawad R, et al. Longitudinal study of bone mineral density and vitamin D levels among perinatally HIV-infected Thai adolescents on long-term antiretroviral therapy. Kuala Lumpur: Proceedings of the 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2013. Abstract MOPDB0103.

    Google Scholar 

  19. Yin MT, Lund E, Shah J, et al. Lower peak bone mass and abnormal trabecular and cortical microarchitecture in young men infected with HIV early in life. AIDS. 2013. doi:10.1097/QAD.0000000000000070. This study confirms that HIV infection in childhood contributes to a failure of infected young adults to reach peak bone mass. Furthermore, the quality of bone is also compromised. While we can only speculate about long-term consequences, these early deficiencies in bone formation will likely leave HIV-infected young adults at high risk of subsequent fractures.

    Google Scholar 

  20. Jiminez B, Sainz T, Diaz L, et al. Low bone mineral density in vertically HIV+ adolescents: inflammation, immune activation, and HIV-related factors. Atlanta: Proceedings of the 20th Conference on Retroviruses and Opportunistic Infections; 2013. Abstract 964.

    Google Scholar 

  21. Grant PM, Kitch D, McComsey GA, et al. Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis. 2013;57(10):1483–8. The importance of early initiation of ART extends beyond immunologic benefits and also reduces the likelihood of metabolic complications of HIV, including BMD loss.

    Article  CAS  PubMed  Google Scholar 

  22. Erlandsen K, Kitch D, Tierney C, et al. Change in lean body mass and association with bone mineral density change in subjects randomized to abacavir/lamivudine or tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz: ACTG A5224s. Atlanta: Proceedings of the 20th Conference on Retroviruses and Opportunistic Infections; 2013. Abstract 825.

    Google Scholar 

  23. Titanji K, Vunnava A, Sheth A, et al. B cell dysregulation promotes HIV-induced bone loss. Atlanta: Proceedings of the 20th Conference on Retroviruses and Opportunistic Infections; 2013. Abstract 821.

    Google Scholar 

  24. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000;14:F63–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Hernandez-Vallejo SJ, Beaupere C, Larghero J, et al. HIV protease inhibitors induce senescence and alter osteoblastic potential of human bone marrow mesenchymal stem cells: beneficial effect of pravastatin. Aging Cell. 2013;12(6):955–65. A compelling evaluation of potential mechanisms behind the role of protease inhibitors on bone turnover. The study also demonstrated a potential noncholesterol beneficial effect of statins.

    Article  CAS  PubMed  Google Scholar 

  26. Liu Y, Kitrinos K, Babusis D, et al. Lack of tenofovir alafenamide (TAF) effect on primary osteoblasts in vitro at clinically relevant drug concentrations. Denver: Proceedings of the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2013. Abstract H-664.

    Google Scholar 

  27. National Osteoporosis Foundation. 2013 Clinician’s guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2013. http://nof.org/files/nof/public/content/resource/913/files/580.pdf. Accessed 14 Jan 2014.

  28. Young B, Dao CN, Buchacz K, Baker R, Brooks JT. HIV Outpatient Study (HOPS) Investigators. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis. 2011;52(8):1061–8.

    Article  PubMed  Google Scholar 

  29. Warriner AH, Smith W, Curtis JR, et al. Fracture among older and younger HIV+ Medicare beneficiaries. Atlanta: Proceedings of the 20th Conference on Retroviruses and Opportunistic Infections; 2013. Abstract 820.

    Google Scholar 

  30. Gotti D, Gianizza M, Porcelli T, et al. Bone mineral density and prevalence of asymptomatic vertebral fractures in HIV+ patients on cART. Atlanta: Proceedings of the 20th Conference on Retroviruses and Opportunistic Infections; 2013. Abstract 822.

    Google Scholar 

  31. Battalora L, Buchacz K, Armon C, et al. Low bone mineral density is associated with increased risk of incident fracture in HIV-infected adults. Brussels: Proceedings of the 14th European AIDS Conference; 2013. Abstract PS1/4.

    Google Scholar 

  32. Bedimo R, Maalouf NM, Zhang S, et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26(7):825–31.

    Article  CAS  PubMed  Google Scholar 

  33. Yin MT, Kendall MA, Wu X, et al. Fractures after antiretroviral initiation. AIDS. 2012;26(17):2175–84.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Lo Re 3rd V, Volk J, Newcomb CW, et al. Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection. Hepatology. 2012;56:1688–98.

    Article  PubMed  Google Scholar 

  35. Hansen AB, Gerstoft J, Kronborg G, et al. Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS. 2012;26(3):285–93.

    Article  PubMed  Google Scholar 

  36. Maalouf NM, Zhang S, Drechsler H, et al. Hepatitis C co-infection and severity of liver disease as risk factors for osteoporotic fractures among HIV-infected patients. J Bone Miner Res. 2013;28(12):2577–83.

    Article  PubMed  Google Scholar 

  37. Womack JA, Goulet JL, Gibert C, et al. Veterans Aging Cohort Study Project Team. Physiologic frailty and fragility fracture in HIV-infected male veterans. Clin Infect Dis. 2013;56(10):1498–504.

    Article  PubMed  Google Scholar 

  38. McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV: a practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51(8):937–46. A comprehensive review of the approach to the management of bone disease for HIV care providers.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Edgar T. Overton was a consultant for Gilead Science and Janssen. Edgar T. Overton received a grant from Vertex Pharmaceuticals. Linda A. Battalora has no conflicts. Ben Young was a consultant for Gilead Sciences, Merck & Co, Viiv Healthcare and Bristol-Meyers Squibb, received honoraria from Merck & Co, Viiv Healthcare, Gilead Sciences, Monogram Biosciences and Bristol-Meyers Squibb, and received payment for development of educational presentations from Viiv Healthcare.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Colorado School of Mines, Golden, CO, USA

    Linda A. Battalora

  2. International Association of Providers of AIDS Care, Washington, DC, USA

    Benjamin Young

  3. Apex Family Medicine and Research, Denver, CO, USA

    Benjamin Young

  4. University of Alabama School of Medicine, 908 20th St. S, CCB Room 330A, Birmingham, AL, 35294, USA

    Edgar T. Overton

Authors
  1. Linda A. Battalora
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Benjamin Young
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edgar T. Overton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edgar T. Overton.

Additional information

This article is part of the Topical Collection on HIV/AIDS

Rights and permissions

Reprints and permissions

About this article

Cite this article

Battalora, L.A., Young, B. & Overton, E.T. Bones, Fractures, Antiretroviral Therapy and HIV. Curr Infect Dis Rep 16, 393 (2014). https://doi.org/10.1007/s11908-014-0393-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11908-014-0393-1

Keywords

Search

Navigation